Gastroparesis Epidemiology Forecast 2025-2034

According to a 2023 systematic review, the overall standardized prevalence of gastroparesis varied significantly, ranging from 13.8 to 267.7 per 100,000 adults in studies conducted between 1994 and 2019. Further, two United States studies using community-based databases estimated a prevalence of 21.5 per 100,000 adults and 24.2 per 100,000 adults, respectively.

Gastroparesis Epidemiology Forecast Report Coverage

The “Gastroparesis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of gastroparesis. It projects the future incidence and prevalence rates of gastroparesis across various populations. The study covers age and type as major determinants of the gastroparesis-affected population. The report highlights patterns in the prevalence of gastroparesis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of gastroparesis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Gastroparesis: Disease Overview

Gastroparesis is a condition in which the stomach empties food into the small intestine more slowly than normal. This leads to symptoms like nausea, vomiting, bloating, and abdominal pain. In this condition, the muscles in the stomach do not function properly, often due to nerve damage. Diabetes is a major risk factor for gastroparesis, especially when blood sugar levels are poorly controlled. It can damage the vagus nerve over time. Certain medications, particularly those that affect stomach motility, can also cause gastroparesis.

Gastroparesis: Treatment Overview

Prokinetic drugs, such as metoclopramide and domperidone, are prescribed to help stimulate the stomach muscles to improve motility. For managing nausea and vomiting, medications like ondansetron or granisetron can help address the symptoms. Proton pump inhibitors or H2 blockers may be recommended if acid reflux is a problem. Proper management of blood sugar levels is advised for diabetic patients, as uncontrolled blood sugar can worsen gastroparesis.

Epidemiology

The gastroparesis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for gastroparesis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for gastroparesis and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Prevalence data for gastroparesis in the United States varies due to differences in measurement methods. One recent study, using a health insurance database, found a prevalence of 267.7 per 100,000 adults. However, estimates based on regression models suggest that gastroparesis could affect as much as 1.8% of the population.
• The standardized prevalence of gastroparesis varied widely, ranging from 13.8 to 267.7 per 100,000 adults, based on studies conducted between 1994 and 2019, according to a 2023 systematic review.
• Studies show that the incidence of gastroparesis is four times higher in women than in men and increases with age in both sexes.
• As per a 2022 study published in Gastroenterology, the most common cause of gastroparesis was diabetes, accounting for 57.4% of cases (with 5.7% having type 1 and 51.7% having type 2 diabetes). This was followed by postsurgical (15.0%), drug-induced (11.8%), and idiopathic (11.3%) causes.

Country-wise Gastroparesis Epidemiology

The gastroparesis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of gastroparesis varies significantly between countries due to differences in the prevalence of underlying conditions such as diabetes, healthcare access, diagnostic practices, dietary habits, and genetic factors. Additionally, the level of public awareness, healthcare infrastructure, and socioeconomic conditions also impact the prevalence rates. In the United Kingdom, the prevalence of diagnosed gastroparesis was reported to be around 13.8 per 100,000 persons.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of gastroparesis based on several factors.
• The Gastroparesis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of gastroparesis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of gastroparesis epidemiology in the 8 major markets?
• What will be the total number of patients with gastroparesis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of gastroparesis in the 8 major markets in the historical period?
• Which country will have the highest number of gastroparesis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of gastroparesis during the forecast period of 2025-2034?
• What are the currently available treatments for gastroparesis?
• What are the disease risks, signs, symptoms, and unmet needs of gastroparesis?

This product will be delivered within 3-5 business days.